BiotechTube
Home/Esperion Therapeutics (2)/Benjamin Halladay
BH

Benjamin Halladay

Chief Operating Officer and General Counsel

Esperion Therapeutics (2)

Therapeutic Areas

Cardiovascular DiseaseMetabolic Disorders

Esperion Therapeutics (2) Pipeline

DrugIndicationPhase
Bempedoic Acid (NEXLETOL)Primary Hyperlipidemia & Heterozygous Familial Hypercholesterolemia (HeFH)Approved
Bempedoic Acid / Ezetimibe FDC (NEXLIZET)Primary Hyperlipidemia & Heterozygous Familial Hypercholesterolemia (HeFH)Approved
Bempedoic AcidCardiovascular Risk ReductionRegulatory Review

Leadership Team at Esperion Therapeutics (2)

SK
Sheldon Koenig
President, Chief Executive Officer, Director
MG
Mark Glickman
Senior Vice President, Chief Business Officer
JM
JoAnne M. Foody, M.D., FACC, FAHA
Chief Medical Officer
TM
Timothy M. Mayleben
Former President & CEO
AG
Andrew G. Saik
Director
JP
John P. Parrish
Chairman of the Board
View full Esperion Therapeutics (2) profile